Abu Dhabi successfully completes first groundbreaking stem cell trial for knee osteoarthritis
Developed by Swedish biotech company Cellcolabs, StromaForte has shown a favourable safety profile and significant therapeutic potential for knee osteoarthritis, marking a significant step in evaluating cell-based therapies for degenerative joint diseases.
The study evaluated the regenerative properties of Mesenchymal Stem Cells (MSCs), a type of stem cell known for its ability to reduce inflammation and repair and regenerate damaged tissues. Found naturally in the body, MSCs function as biological mediators by detecting areas of stress or injury and signalling the body to initiate its own healing process, rather than simply replacing damaged cells.
In this clinical trial, patients received MSC injections derived from carefully screened healthy donors aged 18-30, directly into their affected knee joints. The goal was to confirm safety, ease pain, reduce inflammation and potentially repair cartilage damage, offering a potential alternative to surgery for those suffering from knee osteoarthritis.
The clinical trial was led by Dr. Oussama Chaar, consultant Orthopedic Surgeon and Dr. Veerabahu Muthusamy, specialist Orthopedic Surgeon, and conducted at Burjeel Medical City and Burjeel Hospital from November 2023 to October 2024, where patients received a single dose of 50 million MSCs via ultrasound-guided injections. The results of the first phase (Phase I/II) of the trial have been encouraging, meeting its primary endpoint of safety confirmed by an independent safety monitoring board.
Patients reported a significant reduction in pain levels, as measured by the Visual Analogue Scale (VAS), and an overall improvement in their quality of life, enabling them to move more comfortably and engage in daily activities with greater ease. Importantly, the treatment was well tolerated, with no serious adverse events reported.
To further evaluate the therapy's efficacy, provide deeper insights into the therapy's impact, MRI scans have been conducted with detailed findings set to be presented at Abu Dhabi Global Health Week in April 2025.
'The successful completion of this clinical trial is a testament to Abu Dhabi's robust regulatory oversight and its growing appeal as a hub for cutting-edge medical research. At the Department of Health – Abu Dhabi, we are committed to fostering a dynamic ecosystem that accelerates innovation while ensuring the highest standards of safety and ethics," Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health — Abu Dhabi, said.
"By prioritising cell and gene therapies and regenerative medicine, we are paving the way for transformative treatments that improve patient outcomes and quality of life. These efforts reaffirm Abu Dhabi's position as a global leader in pioneering health innovations and shaping the future of precision medicine," she added.
The clinical research was made possible through strong collaborations with global experts Cellcolabs, a member of Abu Dhabi's Hub71 global tech ecosystem, worked closely with DoH and Burjeel Medical City to bring this advanced stem cell treatment to patients in the UAE.
Peter Ekstedt, CEO Cellcolabs UAE, commented, 'This clinical trial is a major milestone in Abu Dhabi's journey to becoming a global leader in regenerative medicine. At Cellcolabs, we are proud to contribute with our expertise in stem cells, to bring innovative, evidence-based solutions to patients suffering from knee osteoarthritis. By combining DOH's commitment to healthcare innovation with our advanced stem cell technology and know-how, we are paving the way for safer, more effective, and non-surgical treatments that can change the lives of thousands of patients suffering from OA in UAE.'
Prof. Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, added, 'The success of the StromaForte trial is an exemplary showcase of Abu Dhabi's growing biotechnology sector. With continued research and development, stem cell therapy could transform osteoarthritis treatment, offering patients a non-surgical option for pain relief and improved mobility.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
2 hours ago
- Al Etihad
Abu Dhabi: Malaffi reaches 3.5 billion clinical records
14 Aug 2025 11:36 ABU DHABI (ALETIHAD) Malaffi, the region's first Health Information Exchange (HIE) platform and a strategic initiative of the Department of Health – Abu Dhabi (DoH), operated by M42's Abu Dhabi Health Data Services (ADHDS), has achieved a significant milestone by reaching 3.5 billion clinical records, representing 12.7 million unique patient profiles across Abu Dhabi to help progress the UAE's advance in precision and preventive care. The milestone highlights Malaffi's ongoing evolution as a cutting-edge Health Information Exchange platform that supports innovation and excellence in the delivery of healthcare services. Malaffi continues to improve healthcare professionals' access to and utilisation of critical patient information. With connections to nearly all healthcare facilities – including hospitals, clinics and pharmacies - in the Emirate, Malaffi now supports 53,476 authorised users, from doctors and nurses to allied health professionals across 3,072 healthcare facilities in Abu platform's latest enhancements expand its capabilities with the addition of over 160,000 M42 Pharmacogenomics Reports, offering personalised insights into patients' genetic responses to medications to optimise treatment plans. Furthermore, new diagnostic test results across key specialities—such as Mental Health, Ophthalmology, Otolaryngology, and Respiratory Diagnostics—provide clinicians with deeper insights to elevate patient advancements are complemented by features like the Radiology Image Exchange, allowing access to radiology images from over 60 facilities to all authorised clinical users, and the AI-powered Patient Risk Profile, which predicts risks for chronic conditions and acute events. Together, these innovations streamline workflows, enhance decision-making and support better healthcare Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH), said: 'Malaffi's access to 3.5 billion medical records marks a pivotal milestone, reflecting the Department of Health – Abu Dhabi's steadfast commitment to creating the world's most intelligent, patient-centric healthcare system." She added: "By harnessing innovative healthcare solutions powered by artificial intelligence, such as pharmacogenomics and predictive analytics, Malaffi continues to advance, enabling healthcare providers to deliver services that meet the highest standards of care and empower community members to lead healthier lives. This achievement further strengthens Abu Dhabi's position as a globally leading digital healthcare ecosystem.'Kareem Shaheen, CEO of M42's Digital Health Solutions platform, added: "This milestone is a testament to the collaborative efforts of Abu Dhabi's healthcare ecosystem and the visionary leadership of the Department of Health." He added: "Aligned with M42's mission to advance innovation in health for people, Malaffi is securely connecting critical patient information with clinicians to enable informed decision-making, elevate healthcare standards and deliver quality patient outcomes. With every new feature and service we introduce, we are revolutionising the way care is delivered, ensuring better outcomes for patients and providers alike." With 3.5 billion clinical records now connected, Malaffi plays a key role in enhancing Abu Dhabi's healthcare ecosystem and providing a strong foundation for research, from AI-driven analytics to advanced treatments. As Abu Dhabi progresses in its digital transformation, Malaffi supports the Emirate's growth by offering innovative solutions that benefit patients and providers, reinforcing its position as a global hub for healthcare innovation. Source: Aletihad - Abu Dhabi
Khaleej Times
8 hours ago
- Khaleej Times
UAE: Open book exams in some CBSE schools soon; teachers to be trained
As students in the UAE prepare for Open-Book Assessments (OBAs), some CBSE-affiliated schools are ramping up efforts to equip teachers with the skills they need to navigate these new types of tests. The Central Board of Secondary Education (CBSE) has approved the introduction of OBAs for Class 9 starting in the 2026-27 academic year. The move follows a pilot study that showed strong teacher support for the approach. Although schools will be encouraged to follow the framework, its adoption will be voluntary. Shining Star International School in Abu Dhabi, Principal Abhilasha Singh drew upon her own experiences. 'I remember being in Grade 9 when the Government of India first piloted this for the Uttar Pradesh (state) Board. We were excited to have the textbook as an ally, but it wasn't easy to find answers if you hadn't thoroughly read the book.' Headteachers emphasized that the decision is in alignment with the National Curriculum Framework 2023, which underscores the need to transition from rote memorization to competency-based learning. Muhammad Ali Kottakkulam, Principal of Cosmopolitan International School in Ajman, said, 'The proposal, based on a pilot study, is to incorporate OBA into three pen-paper tests conducted each term in languages, Mathematics, Science, and Social Science. The pilot study indicated that students are facing challenges in effectively utilising resources, grasping interdisciplinary concepts, and applying critical thinking and problem solving skills." The focus, he said, will be "on equipping teachers with the skills to design application-based questions, how to effectively implement them into the classroom settings, and how to monitor student progress and evaluate their performance in an OBA format.' CBSE has previously explored open-book assessments; in 2014, it launched the Open Text Based Assessment (OTBA) for Class 9, covering subjects like Hindi, English, Mathematics, Science, and Social Science. Principals noted that the program was later extended to Class 11 for subjects including Economics, Biology, and Geography, but it was discontinued in the 2017–18 academic year due to its limited effectiveness in fostering critical thinking skills. 'I strongly recommend that questions be application-oriented, demanding analysis, synthesis, and problem-solving,' said Shiny Davison, Principal of Woodlem Park School in Hamidiya, Ajman. 'CBSE will provide guidelines, sample papers, and question-design frameworks, with an optional rollout allowing schools time to adapt. As a school leader, my priority is building teacher capacity through training, workshops, and master-trainer support to create and assess higher-order questions. If implemented with thoughtful design and phased adoption, OBAs can deepen understanding, ease exam stress, and prepare students for real-world challenges.'
Gulf Today
15 hours ago
- Gulf Today
Aunt's heroic donation saves nephew as UAE doctors perform youngest infant liver transplant
A five-month old 4.4-kilogramme Emirati boy, stricken with a rare unpreventable recessive X disorder, and the youngest recipient of a donated liver in the UAE, courtesy of his 37-year-old paternal aunt, shall now be on lifelong monitoring and treatment. Fifth child Ahmed Al Yassi is recuperating at the Burjeel Medical City-Paediatric Intensive Care Unit (BMC-PICU) since his April 4, 2025 12-hour ultra-delicate transplantation. His giant strength, and his family's and the medical team's indefatigability, serve as an inspiring testimony for the August 13 'World Organ Donation Day." The WODD 2025 theme is 'Answering the Call,' for the continuous correct information dissemination on the necessity to grant one's organ/s to save lives. In the UAE, since 2017, is the Ministry of Health and Prevention-spearheaded National Programme for Donation and Transplantation of Human Organs and Tissues-Hayat Programme. According to a press statement, quoting undersecretary, Dr. Mohammed Salim Al Olama, it has been boosted with advanced digital solutions and artificial intelligence that guarantees transparency and efficiency at every stage of organ donation and transplantation process. Its website as of 4:30 p.m. of August 13 had '37,298 registered donors.' From a press statement quoting Department of Health-Abu Dhabi undersecretary Dr. Noura Khamis Al Ghaithi, 1,380 transplantations, through the Hayat Programme, were carried out from 2017 to 2024. The 2024 were at 290: seven heart, 142 kidney, 117 liver, 22 lung, and two pancreas. Over at BMC, elated was Ahmed's father Yahya: 'My baby's recovery is nothing short of a miracle. We were once a family living in fear of losing another child due to a liver problem. I hope our story inspires others to come forward, to learn more, and consider becoming donors. You never know whose life might change.' Abdominal Transplant and Hepato-Pancreatic Biliary surgeon Dr. Johns Shaji Mathew confirmed that Ahmed shall receive 'lifetime monitoring and therapy that includes immunosuppressive medications to prevent organ rejection, while the transplant on Ahmed has resolved the liver-related complications.' 'Ahmed will be regularly supervised by liver and genetics specialists for ongoing evaluation,' added Mathew, among the multi-disciplinary team members, led by Burjeel Abdominal Multi-Organ Transplant Programme-Transplant Surgery director Dr. Gourab Sen. The other on-case Transplant Team were Anaesthesia Division chairperson Dr. Ramamurthy Baskaran and specialists Dr. George Jacob and Dr. Anshu S., and Paediatric Intensive Care Unit (PICU) consultant Dr. Kesava Ramakrishnan. Their advice: 'urgent transplantation.' Ahmed's health debilitated due to the rise of his liver enzymes immediately birth. His diagnostics demonstrated that he is afflicted with ATP6AP1-Congenital Disorder of Glycosylation (ATP6AP1-CDG). Instrumental were the 'family's conviction' and the bravery-cum-volunteerism of mother-of-five Haifaa, Yahya's sister-in-law, who passed all compatibility tests. She and Ahmed are A+ blood type. Mathew said: 'The family's conviction came from the fact that without a transplant, Ahmed's survival chances were extremely low. They already experienced the loss of an older son to similar complications, which made them determined not to lose another.' 'The doctors gave us new hope. My sister-in-law gave us life again,' said Yahya. The USA-headquartered public-private-supported Frontiers in Congenital Disorders of Glycosylation (FCDG) portal notes that ATP6AP1-CDG generally affects males at one every one million. Ahmed has so far become the 31st survivor. There are 30 in other countries. The oldest patient is age 67. ATP6AP1-CDG 'age onset' range from the mother's pregnancy to age two, notes the Orphanet Knowledge on Rare Diseases and Orphan Drugs. From the FCDG, patients 'may have variable degree of liver dysfunction and immunodeficiency with recurrent infections.' Impaired-ness include developmental delays; abnormal body movement; gastrointestinal, urinary and genital problems; congenital heart defects and blood syndromes. So far, the solution is 'liver transplantation which has been successful in patients with severe liver failure.' Mathew said decreased transmission would only be via 'genetic screening and pre-marital genetic counselling to identify carriers and inform reproductive decisions for families with a known history.' Ahmed's family history has 'his grandfather passed on in 2010 due to a liver disease.' From the BMC Transplant Team that encourages a well-informed community on organ donation and transplantation: 'Ahmed's survival underscores the transformative power of organ donation and the advanced capabilities we now have in the UAE to perform complex, high-stakes surgeries for even the tiniest patients. Liver transplantation is not just surgical procedure; it is a second chance at life for those with no other options.'
